Skip to main content

ICT Enabled Prediction of Cancer Reoccurrence

Project description

Virtual Physiological Human NeoMark will record and combine heterogeneous clinical, laboratory, molecular and imaging data to develop a data integration environment facilitating multiscale and multilevel modelling.

Objectives of the project

The clinical problem
The continuous improvement in treatment protocols for neoplastic diseases has substantially increased the number of patients who achieve a complete disappearance of the disease after treatment. At this stage there are no clinical, laboratory or imaging evidences of the neoplastic mass, but there can still be invisible residual disease that can evolve overtime and metastasize. A strict follow-up is usually undertaken and adjuvant treatments are planned to reduce the risk of disease reoccurrence, however they have important side-effects that may harm also patients who are already completely recovered. Knowing in advance which patients have the higher risk of disease reoccurrence would be important to focus resources and initiate adjuvant treatments only in a limited, high-risk subgroup of patients and would allow starting an appropriate treatment in time with the potential to improve patient survival and quality of life.

NeoMark will pursue the identification of imaging and genomic/ proteomic markers aimed at modelling recurrence of neoplastic disease with two major clinical/scientific purposes:
1. identify subjects at higher risk of reoccurrence after reaching remission;
2. early diagnose the presence of a reoccurrence.
The technical target of NeoMark will be the development of two functional environments: one for the definition of biomarker profiles and one for the follow-up of the evolution of the disease.

Expected Results & Impacts
Oral cancer holds the eight position in the cancer incidence ranking worldwide, squamous cell carcinoma representing 5% of all cancers for men and 2% for women (WHO). Patients with oral cancer have to deal with the impact of the disease and its treatment on physical appearance and on the ability to eat and to speak, with a significant decrease of the quality of life. Despite advances in salvage treatment of patients with recurrent cancer, outcomes for re-treatment are generally poor. Hence the importance of the identification of specific “markers” for oral cancer whose appearance during follow-ups will enable early and softer interventions and decrease the risks of death.
NeoMark expects to develop a system able to early detect the “markers” specific for oral cancer and so enable:
• early and more specific diagnosis of cancer reoccurrences;
• more targeted and effective interventions based on the patient-specific disease profile;
• avoiding unnecessary treatments for patients at very low risk of reoccurrence;
• optimising the work of physicians and the usage of resources;
• improving the scientific and medical knowledge on oral cancer processes;
• improve patients’ quality of life;
• increase the life duration for patients with cancer reoccurrence.

Field of science

  • /medical and health sciences/clinical medicine/oncology/cancer

Call for proposal

FP7-ICT-2007-2
See other projects for this call

Funding Scheme

CP - Collaborative project (generic)

Coordinator

AZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA
Address
Via Gramsci 14
43100 Parma
Italy
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
EU contribution
€ 707 776
Administrative Contact
Michele MALANCA (Mr.)

Participants (9)

FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
Germany
EU contribution
€ 399 663
Address
Hansastrasse 27C
80686 Munchen
Activity type
Research Organisations
Administrative Contact
Christoph Schulte (Mr.)
UNIVERSIDAD POLITECNICA DE MADRID
Spain
EU contribution
€ 172 404
Address
Calle Ramiro De Maeztu 7 Edificio Rectorado
28040 Madrid
Activity type
Higher or Secondary Education Establishments
Administrative Contact
GONZALO LEON (Prof.)
FUNDACION MD ANDERSON INTERNATIONAL ESPANA
Spain
EU contribution
€ 205 190
Address
Calle Gomez Hemans 2
28033 Madrid
Activity type
Research Organisations
Administrative Contact
ISABEL CRESPO (Ms.)
PANEPISTIMIO IOANNINON
Greece
EU contribution
€ 310 000
Address
Panepistemioypole Panepistemio Ioanninon
45110 Ioannina
Activity type
Higher or Secondary Education Establishments
Administrative Contact
GEORGIOS DETSIKAS (Mr.)
PLANET S.A

Participation ended

Greece
EU contribution
€ 184 912
Address
Louise Riencourt 64, Apollon Tower
11523 Athens
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
NIKOLAOS KOUTRETSIS (Mr.)
ISTITUTI FISIOTERAPICI OSPITALIERI
Italy
EU contribution
€ 63 000
Address
Via Chianesi 53
00144 Roma
Activity type
Other
Administrative Contact
ENRICO DEL BAGLIVO (Mr.)
STMICROELECTRONICS SRL
Italy
EU contribution
€ 210 314
Address
Via C.olivetti 2
20864 Agrate Brianza
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
MARIA GRAZIA PODESTA' (Dr.)
MULTIMED S.R.L.
Italy
EU contribution
€ 357 600
Address
Via Portinari Del Po 21
26100 Cremona
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Diego Ardigò (Dr.)
LINK CONSULTING - TECNOLOGIAS DE INFORMACAO S.A.
Portugal
EU contribution
€ 285 741
Address
Avenida Duque D'avila 23
1000-138 Lisboa
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Pedro Sousa (Prof.)